Bayer Radiology
Bayer is a leader in medical imaging solutions, serving healthcare professionals and institutions worldwide.
Building on nearly a century of expertise, Bayer Radiology transforms clinical insight into innovative technologies that help support diagnostic accuracy, inform healthcare decisions and enable confident patient care.
Its extensive portfolio spans contrast agents, precision injection systems and fluid delivery devices for CT, MR, PET and CV, supported by connected technologies, imaging software and dedicated equipment services.
Connected Imaging Solutions
Bayer’s radiology portfolio is purposefully connected to support imaging departments across the diagnostic continuum of care.
Bayer’s advanced power injectors and fluid delivery systems are engineered for precise, consistent dosing and seamless workflow integration in high-volume clinical environments.
Scale and Reach
Across care settings, Bayer Radiology solutions support clinicians in diagnosing and managing disease.
As of 2026, Bayer has solutions in approximately 21,000 hospitals nationwide – including 95% of the top 50 U.S. hospitals. Across these institutions, more than 34,000 Bayer power injectors are in use, playing a critical role in diagnostic imaging for oncologic, cardiovascular, neurological and other conditions.
Globally, as of 2026, Bayer Radiology and Product Supply organizations produce solutions that support an estimated 60 million patients each year.
Innovation and Product Development
Innovation remains central to Bayer Radiology’s strategy. The company continuously advances its injection systems and imaging solutions to improve clinical performance, usability and sustainability.
For example, newer-generation systems are developed using human factors engineering principles to ensure they are intuitive for technologists to operate in clinical practice while minimizing the potential for error. Product development efforts also incorporate material efficiencies and environmentally conscious design considerations, reducing resource use without compromising performance.
Digital and Informatics Capabilities
Beyond hardware and contrast agents, Bayer invests in digital and informatics capabilities that help imaging departments optimize operations.
Connected technologies enable data-driven insights into workflow, equipment utilization, and performance metrics, supporting customer quality assurance initiatives and helping facilities manage increasing imaging volumes.
As healthcare systems face growing pressure to deliver high-quality care efficiently, these digital tools provide added value by enhancing operational visibility and performance management.
Field Service and Support
Bayer deploys a direct, highly trained field service model designed to maximize equipment uptime and reliability.
Field service representatives are available 24/7 to triage and address customer needs, carrying extensive parts inventories to minimize disruptions.
This proactive and responsive service approach helps ensure that imaging systems remain operational so patients can receive timely scans and diagnoses when they need them most.
Advancing the Future of Medical Imaging
Guided by the belief that everyone deserves clear answers about their health, Bayer continues to invest in innovation that helps enhance diagnostic confidence, improve patient care and strengthen partnerships with healthcare providers.
By integrating advanced imaging technology, digital capabilities and responsive service at scale, Bayer Radiology remains a trusted collaborator in shaping the future of medical imaging worldwide.
May 7, 2026
The Phase III REVEAL study met its primary endpoints demonstrating sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide) positron emission tomography computed tomography (PET/CT) for the diagnosis of cardiac amyloidosis based on visual scan interpretation
--------------
March 4, 2026
Expanded Tesla compatibility captures low- to high-end field magnetic resonance (MR) systems, now supporting up to and including 7T
--------------
January 12, 2026
Bayer bolsters development portfolio by acquisition of two investigational imaging agents (AT-01 and AT-05) from Attralus, Inc. to advance diagnosis for cardiac amyloidosis
--------------
December 1, 2025
Radiology suites now have the ability to further manage contrast consumption and waste, while providing greater flexibility for those transitioning to bulk contrast use
--------------
August 26, 2025
Gadoquatrane New Drug Application Accepted for Review by U.S. FDA